Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novavax's dividends per share for the
three
months ended in Mar. 2026 was MXN0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0.00. Its Dividend Payout Ratio for the
three
months ended in Mar. 2026 was 0.00. As of today, Novavax's Dividend Yield % is 0.00%.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax Dividends per Share Related Terms
Novavax Dividends per Share Historical Data
* Premium members only.
The historical data trend for Novavax's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVAX vs JBIO, AVLN, TRAX: Dividends per Share Comparison
For the Biotechnology subindustry, Novavax's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Novavax's Dividend Yield % falls into.
Novavax (MEX:NVAX) has a Dividends per Share of MXN0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Novavax and its competitors.
Is Novavax's Dividends per Share too high?
Novavax's current Dividends per Share is MXN0.00. Overall, Novavax has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Dividends per Share compare to JBIO and AVLN?
Novavax's Dividends per Share of MXN0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Novavax and its competitors. Novavax's current Dividends per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN64.32, compared to a current price of MXN128.12 — trading 99.2% above its estimated fair value. The current Dividends per Share is MXN0.00. Novavax's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Dividends per Share is MXN0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (MEX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of MXN128.12 is trading 99.2% above its estimated GF Value™ of MXN64.32.
GuruFocus considers Novavax to be Significantly Overvalued.
Key valuation signals for MEX:NVAX:
Dividends per Share: MXN0.00
GF Value™: MXN64.32 vs. price of MXN128.12 (99.2% above fair value)
No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
44GF Score
Get the complete analysis for MEX:NVAX
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVAX has been successfully added to your 
